TELA Bio, Inc. (TELA) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025. TELA Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions, primarily through its OviTex (hernia repair) and OviTex PRS (plastic and reconstructive surgery) product portfolios. The company operates as a single reportable segment and relies on an exclusive contract manufacturer, Aroa Biosurgery Ltd., for its core products.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $20.7 million | $19.0 million | $59.4 million | $51.7 million |
| Gross Profit | $14.0 million | $12.9 million | $40.6 million | $35.3 million |
| Gross Margin | 68% | 68% | 68% | 68% |
| Net Loss | $(8.6) million | $(10.4) million | $(29.8) million | $(28.6) million |
| Net Loss Per Share (Diluted) | $(0.19) | $(0.42) | $(0.66) | $(1.16) |
| Cash and Equivalents | $29.7 million (as of Sept 30, 2025) | |||
| Working Capital | $39.1 million (as of Sept 30, 2025) | |||
| Long-Term Debt | $41.5 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $388.5 million (as of Sept 30, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 9% quarter-over-quarter and 15% year-over-year (YTD). Growth was driven by new customer acquisition, international expansion, and the launch of larger OviTex PRS configurations. Unit sales for OviTex increased 22% and OviTex PRS increased 3% in Q3.
- Operating Expenses: Total operating expenses decreased 3% in Q3 and 1% YTD. Sales and marketing expenses declined 8% in Q3 due to lower severance and travel costs, partially offset by higher commissions. R&D expenses increased 14% in Q3 due to higher study costs.
- Net Loss Improvement: Q3 net loss narrowed by 17% compared to the prior year. However, YTD net loss increased slightly by 4% compared to 2024, primarily because the prior year included a one-time $7.6 million gain from the sale of the NIVIS product line, which did not recur in 2025.
- Cash Position: Cash and cash equivalents decreased from $52.7 million at year-end 2024 to $29.7 million at September 30, 2025, reflecting a net cash burn of $23.3 million from operating activities over the first nine months of 2025.
Guidance, Outlook, and Risks
- Liquidity and Financing: Management believes current resources, combined with recent financing, are sufficient for operations for at least 12 months.
- Debt Refinancing: Subsequent to quarter-end (Nov 14, 2025), the company closed a new credit facility with Perceptive Advisors for up to $70.0 million to repay the existing MidCap facility. The new facility matures in 2030.
- Equity Offering: An underwritten registered direct offering was executed (Nov 13, 2025) expected to close Nov 17, 2025, raising approximately $13.0 million.
- Product Pipeline: The company continues to enroll patients in the BRAVO II study (robot-assisted hernia repair) and the OPERA study (breast reconstruction). FDA approval for an investigational device exemption for OviTex PRS in breast reconstruction was received in October 2024.
- Risks:
- Tariffs: A 15% U.S. tariff on imports from New Zealand (where products are manufactured) is currently shared equally with the manufacturer but could impact pricing and demand.
- Macroeconomics: Risks include hospital financial strain, supply chain disruptions for critical surgical supplies, and potential deferrals of elective procedures.
- Debt Covenants: The company must maintain minimum net revenue levels under its credit agreements.
Investor Verification Checklist
- Verify the closing of the $70.0 million Perceptive credit facility and the $13.0 million equity offering to confirm liquidity runway.
- Monitor the impact of the 15% New Zealand tariff on product pricing and gross margins in future quarters.
- Track progress on the OPERA clinical study for OviTex PRS breast reconstruction indication, a key growth driver.
- Review the composition of "Other" revenue ($0.4M in Q3) to understand non-core product performance.
- Assess the sustainability of the 68% gross margin given potential cost increases from tariffs or supply chain volatility.